Better Therapeutics Inc (BTTX)
$0.00
$-0.01
(-99.15%)
As on 29-Jan-2025 15:00EDT
Market cap
$0 Mln
Revenue (TTM)
$0 Mln
P/E Ratio
--
P/B Ratio
2.3
Div. Yield
0 %
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
$-24 Mln
-
ROE
-10.2 %
-
ROCE
-- %
-
Industry P/E
--
-
EV/EBITDA
-0.5
-
Debt to Equity
-0.8
-
Book Value
$--
-
EPS
$-1.2
-
Face value
--
-
Shares outstanding
54,515,600
5 Years Aggregate
CFO
$-97.82 Mln
EBITDA
$-76.42 Mln
Net Profit
$-123.85 Mln
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Better Therapeutics Inc (BTTX)
| -- | -- | -- | -99.9 | -97.0 | -- | -- |
|
BSE Sensex*
| -10.8 | -0.6 | -1.7 | -8.5 | 6.4 | 7.6 | 11.0 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2023
|
2022
|
|---|---|---|
|
Better Therapeutics Inc (BTTX)
| -82.4 | -76.2 |
|
S&P Small-Cap 600
| 13.9 | -17.4 |
|
BSE Sensex
| 18.7 | 4.4 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Better Therapeutics Inc (BTTX)
|
0.0 | 0.0 | 0.0 | -31.6 | -- | -- | -- | 2.3 |
| 0.0 | 0.1 | 0.0 | -12.4 | -65,168.4 | -147.7 | -- | 0.0 | |
| 1.9 | 20.3 | 0.0 | -27.7 | -640,975.0 | -240.9 | -- | 1.3 | |
| 153.5 | 31,725.8 | 0.0 | -1,371.7 | -- | -88.6 | -- | 22.0 |
Shareholding Pattern
View DetailsAbout Better Therapeutics Inc (BTTX)
Better Therapeutics, Inc., a prescription digital therapeutics company, develops a form of cognitive behavioral therapy to address the causes of cardiometabolic diseases. The company's lead product candidate is BT-001, an investigational PDT platform... to treat type 2 diabetes. It also develops software-based prescription digital therapeutics platform candidates for treating diabetes, heart disease, and other cardiometabolic conditions. In addition, the company's clinical development candidates are intended to treat cardiometabolic diseases, including type 2 diabetes, hypertension, hyperlipidemia, non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, and chronic kidney disease. Its product pipeline also includes BT-002, which intends glycemic control for hypertension; BT-003 to reduce LDL cholesterol in patients with hyperlipidemia; and BT-004, which intends to explore the impact of treatment on liver health in patients with non-alcoholic steatohepatitis/non-alcoholic fatty liver disease. The company was founded in 2015 and is headquartered in San Francisco, California. Read more
-
Co-Founder & Executive Chairman
Mr. David P. Perry M.B.A.
-
Co-Founder & Executive Chairman
Mr. David P. Perry M.B.A.
-
Headquarters
San Francisco, CA
-
Website
Value Research Ratings
Our rating system has guided millions of investors in the past 20 years.
FAQs for Better Therapeutics Inc (BTTX)
What is the current share price of Better Therapeutics Inc (BTTX) Today?
The share price of Better Therapeutics Inc (BTTX) is $0.00 (NASDAQ) as of 29-Jan-2025 15:00 EDT. Better Therapeutics Inc (BTTX) has given a return of -96.97% in the last 3 years.
What is the current PB & PE ratio of Better Therapeutics Inc (BTTX)?
Since, TTM earnings of Better Therapeutics Inc (BTTX) is negative, P/E ratio is not available.
The P/B ratio of Better Therapeutics Inc (BTTX) is 2.29 times as on 29-Jan-2025, a 44 discount to its peers’ median range of 4.07 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2022
|
-0.66
|
-29.19
|
|
2021
|
-2.27
|
2.49
|
|
2020
|
--
|
--
|
|
2019
|
--
|
--
|
|
2022
|
-0.66
|
-29.19
|
What is the 52 Week High and Low of Better Therapeutics Inc (BTTX)?
The 52-week high and low of Better Therapeutics Inc (BTTX) are Rs -- and Rs -- as of 13-Jun-2026.
What is the market cap of Better Therapeutics Inc (BTTX)?
Better Therapeutics Inc (BTTX) has a market capitalisation of $ 0 Mln as on 29-Jan-2025. As per SEBI classification, it is a Small Cap company.
Should I invest in Better Therapeutics Inc (BTTX)?
Before investing in Better Therapeutics Inc (BTTX), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.